# 21 CFR Part 809—In vitro diagnostic products for human use

21 CFR Part 809—In vitro diagnostic products for human use, “In vitro diagnostic products for human use”, is a CFR part of [21 CFR Chapter I, Subchapter H—MEDICAL DEVICES](https://ontology.bommaritollc.com/id/01a0f094-b68f-70af-b8e8-5bb30331a2cf); it is made under 16 laws; in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f094-b894-7577-b5e6-e903d91bd9a5>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter H—MEDICAL DEVICES](https://ontology.bommaritollc.com/id/01a0f094-b68f-70af-b8e8-5bb30331a2cf)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-part 21 CFR Part 809](https://ontology.bommaritollc.com/id/01a0f094-b895-744a-8f22-46388b2bcd44)
- **authority note** (`bcleg:authorityNote`): 21 U.S.C. 321(h)(1), 331, 351, 352, 360, 360c, 360d, 360e, 360h, 360i, 360j, 371, 372, 374, 381, and 42 U.S.C. 262.
- `eli:based_on`:
  - [21 U.S.C. 321 Definitions; generally](https://ontology.bommaritollc.com/id/01a0f06c-cc8c-7030-ab68-1def0b197dcb)
  - [21 U.S.C. 331 Prohibited acts](https://ontology.bommaritollc.com/id/01a0f06c-cc92-7163-972f-ca345be44724)
  - [21 U.S.C. 351 Adulterated drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccc8-7536-94e4-d8e798dad75a)
  - [21 U.S.C. 352 Misbranded drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccca-77a6-a36b-8f6a7374070e)
  - [21 U.S.C. 360 Registration of producers of drugs or devices](https://ontology.bommaritollc.com/id/01a0f06c-ccfb-75a5-8f8d-2899cf8ac727)
  - [21 U.S.C. 360c Classification of devices intended for human use](https://ontology.bommaritollc.com/id/01a0f06c-cd03-765d-83c5-b20037608f38)
  - [21 U.S.C. 360d Performance standards](https://ontology.bommaritollc.com/id/01a0f06c-cd05-77e0-b487-05fcf1974ae2)
  - [21 U.S.C. 360e Premarket approval](https://ontology.bommaritollc.com/id/01a0f06c-cd07-7789-8906-93aab0532034)
  - [21 U.S.C. 360h Notification and other remedies](https://ontology.bommaritollc.com/id/01a0f06c-cd10-74c2-91eb-0ad7ee0450e1)
  - [21 U.S.C. 360i Records and reports on devices](https://ontology.bommaritollc.com/id/01a0f06c-cd12-7312-ba25-7c772f32c7e0)
  - [21 U.S.C. 360j General provisions respecting control of devices intended for human use](https://ontology.bommaritollc.com/id/01a0f06c-cd14-70a5-a599-4fff974986bc)
  - [21 U.S.C. 371 Regulations and hearings](https://ontology.bommaritollc.com/id/01a0f06c-cd7f-7552-9512-d5162892046d)
  - [21 U.S.C. 372 Examinations and investigations](https://ontology.bommaritollc.com/id/01a0f06c-cd80-719d-a261-d5949128e1c5)
  - [21 U.S.C. 374 Inspection](https://ontology.bommaritollc.com/id/01a0f06c-cd83-7175-9624-79d9d7728390)
  - [21 U.S.C. 381 Imports and exports](https://ontology.bommaritollc.com/id/01a0f06c-cdf5-70c8-b8d2-b17f8ad341e4)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol8](https://ontology.bommaritollc.com/id/01a0f094-b894-7577-b5e6-e902137bd38b)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-da3e-70c3-95d7-61eccc62345c)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0cf-7e49-7340-916a-95a793c06029)
  - [evidence from https://www.govinfo.gov/link/cfr/21/809?year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f16-3ecf-75ed-a391-7ef48ed2485d)
- `schema:isPartOf`: [21 CFR Chapter I, Subchapter H—MEDICAL DEVICES](https://ontology.bommaritollc.com/id/01a0f094-b68f-70af-b8e8-5bb30331a2cf)
- `schema:legislationIdentifier`: 21 CFR Part 809
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [CFR part](https://ontology.bommaritollc.com/vocab/leg/cfrPart)
- `schema:name`: In vitro diagnostic products for human use
- `schema:url`: [https://www.govinfo.gov/link/cfr/21/809?year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/809?year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 CFR Part 809—In vitro diagnostic products for human use

## Elsewhere

- [Official page](https://www.govinfo.gov/link/cfr/21/809?year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol8) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Parts (3; `schema:isPartOf`):
  - [21 CFR Part 809, Subpart A—General Provisions](https://ontology.bommaritollc.com/id/01a0f094-b6a2-76a5-ba93-094c055510fb)
  - [21 CFR Part 809, Subpart B—Labeling](https://ontology.bommaritollc.com/id/01a0f094-b6a3-70ef-bac8-7f959b963d50)
  - [21 CFR Part 809, Subpart C—Requirements for Manufacturers and Producers](https://ontology.bommaritollc.com/id/01a0f094-b6a3-70ef-bac8-7fa1fb51fd0d)
- Cited by (2; `eli:cites`):
  - [FR Doc. 2023-21662: Medical Devices; Laboratory Developed Tests](https://ontology.bommaritollc.com/id/01a110b2-d7ed-7561-a6db-9def299ca7ac)
  - [FR Doc. 2024-08934: Enforcement Policy for Certain In Vitro Diagnostic Devices for Immediate Public Health Response in the Absence of a Declaration Under Section 564; Draft Guidance for Laboratory Manufacturers and Food and Drug Administration Staff; Availability](https://ontology.bommaritollc.com/id/01a110b3-5a65-7334-b84f-93f838dc2f24)
- Its changes, from (2; `eli:changes`):
  - [FR Doc. 2024-08935: Medical Devices; Laboratory Developed Tests](https://ontology.bommaritollc.com/id/01a110b3-5ae5-76c1-95f9-5570d635fa82)
  - [FR Doc. 2025-18239: Regulation Identification Number 0910-AJ05 Medical Devices; Laboratory Developed Tests; Implementation of Vacatur](https://ontology.bommaritollc.com/id/01a110b4-bafd-763d-a364-f1b92092b1b4)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-b894-7577-b5e6-e903d91bd9a5.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-b894-7577-b5e6-e903d91bd9a5.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-b894-7577-b5e6-e903d91bd9a5.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-b894-7577-b5e6-e903d91bd9a5)
Cite as: 21 CFR Part 809—In vitro diagnostic products for human use. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-b894-7577-b5e6-e903d91bd9a5
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
